Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapsone is a synthetic sulfone antibiotic and anti-inflammatory agent primarily used to treat leprosy (Hansen's disease) and dermatitis herpetiformis. It is also used as a second-line treatment for the prevention of pneumocystis pneumonia and toxoplasmosis in immunocompromised patients. Dapsone acts as a bacteriostatic agent by inhibiting the synthesis of dihydrofolic acid through competitive inhibition of dihydropteroate synthase in susceptible organisms such as Mycobacterium leprae. Its anti-inflammatory effects are distinct from its antimicrobial action and involve modulation of neutrophil activity and other inflammatory mediators. Dapsone has been studied for additional uses including acne vulgaris and various chronic inflammatory skin disorders[1][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dapsone.